Radiooncology / Radiobiology

  • Imaging and Radiooncology

Prof. Dr. med. Dr. h. c. Michael Baumann

Our research group bridges radiobiological research with clinical practice and consistently implements the translational research approach of “byte-to-bench-to-bedside” with the aim of further optimizing cancer therapies. At the same time, we also follow the opposite approach by using clinical observations to uncover and systematically analyse the underlying biological mechanisms of radiotherapy. Operative Division Head: Dr. Ina Kurth

Spheroid

Image: Spheroid,

Our Research

The multidisciplinary work of our group, involving clinicians, biologists, bioinformaticians and physicists, is driving innovation from basic biology to clinical trials, advanced imaging techniques and data analyses in radiobiology and radiation oncology. A central point is to understand the biological heterogeneity of tumours. Despite the personalization of modern radiotherapy, this influences the response of patients to therapy, which leads to different reactions to therapy, resistance and relapses.

With the help of omics data and multiplex biomarkers from imaging, we want to refine the stratification of patients and develop novel, targeted (combination) treatments. Understanding the molecular basis of radioresistance and validating biomarkers in large patient cohorts are key to this.

In collaboration with different working groups from the DKFZ and the German Cancer Consortium (DKTK) and worldwide, our projects focus on:

  • Investigation of radioresistance mechanisms, including hypoxia and tumour heterogeneity.

  • Validation of biomarkers and testing of therapy combinations in preclinical models.

  • Integration of omics, pathology and imaging data for precision medicine.

  • Advancing preclinical and clinical studies via the RadPlanBio platform.

  • Theoretical modelling for analysis and interpretation of tumour evolution and survival datasets.

  • Introduction and development of standardized semantic structures to improve the usability of data across studies and institutions.

     

Outlook

Our research paves the way for clinical trials aimed at individually tailored personalized cancer treatments. Future therapies will shift from single-modality approaches to customized combinations that take into account the unique clinical and biological profile of each patient. By analysing the molecular mechanisms of radioresistance and tumour heterogeneity, we aim to identify key intracellular signalling pathways linked to treatment failure, revealing new druggable targets to enhance radiotherapy effectiveness.

Advanced multiplex histologic imaging parameters will be integrated with clinical and biological data to refine patient stratification to enable precise, effective and minimally invasive treatments with improved outcomes.

Projects

Within the department, there are - next to the subdivisions - various projects on which our research is focused. 

 

1. Tumour Biology and Radiotherapy

HypoxRM - Imaging and Multiomics integration for tumour hypoxia characterization

This research project aims to enhance our understanding and improve therapeutic strategies for squamous cell carcinoma of the head and neck (HNSCC), a malignant tumour arising from various sites in the oral cavity and upper respiratory tract and, despite many treatment options, is still associated with a poor survival prognosis.

Radiation therapy remains a cornerstone of HNSCC treatment. However, therapeutic resistance frequently develops, partly due to hypoxia - regions of the tumour with insufficient oxygen supply. Strategies to sensitize hypoxic cancer cells to radiation, such as enhancing oxygen availability during treatment, have been explored. Interestingly, "reoxygenation" can also occur following radiation exposure, yet this process may paradoxically compromise treatment efficacy. This underscores the critical role of transiently hypoxic tumour regions in influencing patient responses to therapy.

It is now well-recognized that hypoxia is a highly dynamic phenomenon affecting virtually all cell types within the tumour microenvironment, presenting significant challenges for its accurate modelling in laboratory settings. Our primary objective is to bridge the gap between findings from in vitro and in vivo preclinical studies and the complex reality of hypoxia in cancer patients before and during treatment.

To achieve this, we are adopting innovative methodologies to assess oxygenation at the cellular level. Leveraging biobank resources (comprising collections of biological samples) and state-of-the-art imaging technologies, we aim to investigate individual cells and their microenvironment. Through this approach, we seek to elucidate how fluctuating oxygen levels influence cancer cell behaviour and treatment outcomes. Ultimately, our research aspires to pave the way for more effective therapeutic interventions for HNSCC in the presence of hypoxia.

Contact: Maria José Besso

2. Data-Driven Cancer Research

Survival analysis of HNSCC through Histopathology Slides and AI

Together with our collaboration partner in Dresden (Division of Clinical Artificial Intelligence, TU Dresden, Prof. Jakob Kather), we are analysing which potential markers can be extracted from histology slides, particularly hematoxylin and eosin (H&E) stains. For this, foundation models are utilized as rich feature extractors of histopathological characteristics, in combination with attention-based models to weight areas of the images that are associated with survival. These models are either trained on specific molecular characteristics (e.g., omics modalities) or on available clinical data (e.g., follow-up information). With H&E stains being widely available in clinical practice, this method offers a cost-efficient way to identify prognostic features.

Contact: Verena Bitto

3. Theoretical Models in Cancer Research

Propagator Methods for Survival Analysis

In this project, inspired by the concepts and ideas of quantum mechanics, we aim to model the survival of patients and their tumour growth with a patient-near stochastic process. We imagine time-dependent patient data as positional states in an abstract space and try to describe a transition function (propagator) between these states; the parameters of this function can be understood as “natural laws of cancer growth”. In this way, we aim to characterise both deterministic and seemingly random aspects of disease progression and develop a novel method to extract information from survival data, in particular by incorporating temporal evolution. This represents a crucial step for scientific understanding and subsequent individualised clinical treatment.

Contact: Julian Schlecker

4. Data Integration and FAIRification

FAIRification of preclinical and clinical data

Our work focuses on standardizing and formalizing data collected from preclinical and clinical studies to enhance knowledge discovery. We began by standardizing digitized data hosted on the RadPlanBio platform, structuring it according to the SEND standard for nonclinical datasets. The data is then formalized using the Ontology for Preclinical Trials in Radiation Oncology (PTRO). Building on this foundation, we are using Ontop to develop a Virtual Knowledge Graph (VKG) based on the PTRO ontology. This VKG allows users to access and query heterogeneous data sources as a unified graph, without physically moving or duplicating the data. These tools provide a structured and transparent representation of data, ensuring clarity, consistency, and reproducibility across studies. Looking ahead, we are extending these FAIRification efforts to clinical data, paving the way for greater integration, accessibility, and usability across the research continuum.

Contact: Olga Giraldo Pasmin

Team

Our highly interdisciplinary division consists of scientists, technical and documentary assistants as well as students who have received their training in the fields of biology, physics, medicine, bioinformatics and computer science. Experienced scientists work side by side with PhD/MD students and undergraduates to advance our research within the group and in global collaborations.

19 Employees

  • Prof. Dr. med. Dr. h. c. Michael Baumann

    Division Head

    Contact form: Message to Prof. Dr. med. Dr. h. c. Michael Baumann

    Form data is loaded ...

  • Dr. Ina Kurth

    Division Head

    Show profile
    Contact form: Message to Dr. Ina Kurth

    Form data is loaded ...

  • Silke Cardona

    Secretary

    Contact form: Message to Silke Cardona

    Form data is loaded ...

  • Dr. Maria José Besso

    Biotechnologist, Hypoxia and Radioresponsiveness in HNSCC

    Show profile
    Contact form: Message to Dr. Maria José Besso

    Form data is loaded ...

  • Dr. Verena Bitto

    Computational Scientist

    Show profile
    Contact form: Message to Dr. Verena Bitto

    Form data is loaded ...

  • Mahnaz Bonrouhi

    Biological-technical Assistant

    Show profile
    Contact form: Message to Mahnaz Bonrouhi

    Form data is loaded ...

  • Cristina Conde Lopez

    Sex differences in cancer

    Show profile
    Contact form: Message to Cristina Conde Lopez

    Form data is loaded ...

  • Manuela Dittrich

    Biologist

    Show profile
    Contact form: Message to Manuela Dittrich

    Form data is loaded ...

  • Rosemarie Euler-Lange

    Bioengineer

    Show profile
    Contact form: Message to Rosemarie Euler-Lange

    Form data is loaded ...

  • Thomas Früchtel

    Medical Documentation

    Contact form: Message to Thomas Früchtel

    Form data is loaded ...

  • Dr. Olga Ximena Giraldo Pasmin

    Ontology Engineer

    Show profile
    Contact form: Message to Dr. Olga Ximena Giraldo Pasmin

    Form data is loaded ...

  • Dr. Wahyu Wijaya Hadiwikarta

    Head of Knowledge Modelling & RadPlanBio

    Show profile
    Contact form: Message to Dr. Wahyu Wijaya Hadiwikarta

    Form data is loaded ...

  • Priv. Doz. Dr. Jochen Heß

    Clinical Cooperationpartner for Experimental and Translational Head- and Neck-Oncology

    Show profile
    Contact form: Message to Priv. Doz. Dr. Jochen Heß

    Form data is loaded ...

  • Safayat Mahmud Khan

    HPV, Radiosensitivity and Tumor Heterogeneity

    Show profile
    Contact form: Message to Safayat Mahmud Khan

    Form data is loaded ...

  • Carla Popp

    AXL and Radiosensitivity

    Show profile
    Contact form: Message to Carla Popp

    Form data is loaded ...

  • Dr. Mareike Roscher

    Head of Morszeck PCTU

    Show profile
    Contact form: Message to Dr. Mareike Roscher

    Form data is loaded ...

  • Joana Schlag

    Medical Documentation Assistance

    Contact form: Message to Joana Schlag

    Form data is loaded ...

  • Julian Schlecker

    Survival Models

    Show profile
    Contact form: Message to Julian Schlecker

    Form data is loaded ...

  • Büsranur Yilmaz

    Medical Documentation Assistance

    Contact form: Message to Büsranur Yilmaz

    Form data is loaded ...

Entire Team

Get in touch with us

Two scientists looking at a computer monitor
Dr. Ina Kurth
Division Head
Contact form: Message to Dr. Ina Kurth

Form data is loaded ...

Silke Cardona
Secretary
Contact form: Message to Silke Cardona

Form data is loaded ...